Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
about
Serum levels of angiopoietin-2 are associated with the growth of multiple myelomaEx-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapyIncreased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome.Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.Hypoxia inducible factor-1 alpha and multiple myeloma.Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.The hypoxia signalling pathway in haematological malignancies.Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma.Angiogenesis and multiple myeloma.Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma.Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis.Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation.Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall.The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis.
P2860
Q28292520-4514031C-6D17-4E1C-9686-DCEFC0826ABDQ28535634-E68AD70C-5FA3-4D09-99A5-AF99F5C04633Q36366608-50CBC487-3763-4963-9251-6350A6753FFDQ37413352-3C747785-C332-4BB1-B0FC-CD849859018DQ38567828-3F70ECE4-D154-4625-AB58-2868E72095A6Q38647628-46246C51-B0BB-4D65-AF5C-646334C1E24DQ38703298-98694626-3B75-4E4C-A752-2529185C4AFCQ39246376-676EC493-6A04-4599-8016-A393F98F004FQ39527767-010809FC-2E53-4BE9-B926-62CAF42C14D8Q39696428-F2904A06-25B3-4F7A-B2BF-4BB5D0987FA2Q39824985-5DC85BA1-FE20-4709-93C6-837E883524F9Q41208882-EE4DE1F6-96E7-4E70-80BA-A946495E895FQ48049809-F24960B1-A725-4047-8694-8AF58DB381FEQ52535430-7904BE25-F104-406B-A3DE-880DD9117227Q54939127-9E9EDD79-0358-41CC-AF4A-4E784457C12E
P2860
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Circulating angiopoietin-1 to ...... with novel antimyeloma agents.
@en
Circulating angiopoietin-1 to ...... with novel antimyeloma agents.
@nl
type
label
Circulating angiopoietin-1 to ...... with novel antimyeloma agents.
@en
Circulating angiopoietin-1 to ...... with novel antimyeloma agents.
@nl
prefLabel
Circulating angiopoietin-1 to ...... with novel antimyeloma agents.
@en
Circulating angiopoietin-1 to ...... with novel antimyeloma agents.
@nl
P2093
P2860
P356
P1476
Circulating angiopoietin-1 to ...... with novel antimyeloma agents.
@en
P2093
Anastasia Pouli
Athanasios Papatheodorou
Dimitrios Christoulas
Dimitrios Margaritis
Eirini Katodritou
Ekaterini Stefanoudaki
Eurydiki Michalis
Evangelos Terpos
Greek Myeloma Study Group, Greece
John Meletis
P2860
P304
P356
10.1002/IJC.26062
P577
2011-05-30T00:00:00Z